An Early Phase 1 interventional study of aspiration biopsy in Parotid Gland Neoplasms, sponsored by National Institute of Cancerología. Status unknown at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-09-26.
Sponsored by National Institute of Cancerología · Early Phase 1, Interventional, and Diagnostic
Liberal use of fine needle aspiration biopsy of parotid gland masses is controversial. All information regarding this procedure has been retrospective. Our objective is to evaluate prospectively the diagnostic accuracy of the test, alone and when associated to clinical and/or radiologic data.
This is a prospective diagnostic test study. Inclusion criteria are all consecutive patients with parotid gland masses referred for treatment at our center, from January 2003 to December 2007.
The gold standard for the diagnosis of malignancy is the surgical pathology report of the parotidectomy specimen.
Cytologist and pathologist will be blind. Diagnostic accuracy is determinded by Bayesian analysis.
27 studies on the registry are indexed under Parotid Neoplasms; 7 are open to participants now.
This study's planned enrollment of 150 is above the median of 55 across 20 interventional studies indexed under Parotid Neoplasms.
Browse Parotid Neoplasms studies →National Institute of Cancerología is the lead sponsor of 38 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
fine needle aspiration biopsy of the parotid gland mass
Procedure: aspiration biopsy
fine needle aspiration biopsy of the parotid gland masses
Diagnosis of malignancy
Time frame: three years
Specific histopathologic diagnosis
Time frame: three years
This study is status unknown, as verified in Jan 2003. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cancerología